Patents Examined by Taeyoon Kim
  • Patent number: 10837002
    Abstract: The present disclosure relates to: an artificial peritoneal tissue comprising a cellular tissue and a mesothelial cell layer that covers the surface of the cellular tissue, wherein the cellular tissue comprises a fibroblast, an extracellular matrix, and a vascular endothelial cell and/or a lymphatic endothelial cell each capable of forming a lumen; and a method for producing the artificial peritoneal tissue.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 17, 2020
    Assignees: HIROSAKI UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Hiroshi Shimoda, Yoshiya Asano, Mitsuru Akashi, Michiya Matsusaki
  • Patent number: 10821206
    Abstract: Method of the osteoreparative processes' correction and/or bone defect restoration by means of human cell-based products (cell and/or tissue transplants) and the method of its manufacturing. The invention a creates and establishes conditions for osteoreparative processes restoration in destroyed bone tissue by osteoreparation cell sources restoration as the result of use cell technologies and bone tissue engineering methods, e.g. scaffold-guided regeneration, particularly by means of cell transplantation by injection and/or transplantation of original three-dimensional osteoreparative prevascularized graft (3D-OPG). Manufacturing of medical products and preparations of the product based on human cells (cell and/or tissue transplants) is dedicated for impaired osteoreparative processes correction and/or bone defect restoration.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: November 3, 2020
    Assignee: ILAYA USA CORPORATION
    Inventors: Volodymyr Mykhaylovych Oksymets, Dmytro Oleksandrovych Zubov, Roman Hennadiyovych Vasyliev
  • Patent number: 10787688
    Abstract: The invention provides a process for the preparation of hydrocarbons substituted with at least one group containing at least one oxygen atom, comprising the process steps A) reaction of a carbon source comprising at least one selected from CO2 and CO to give acetate and/or ethanol with a first microorganism, B) separating off of the acetate from the first microorganism, C) reaction of the acetate to give a hydrocarbon substituted with at least one group containing at least one oxygen atom with a second microorganism and optionally D) purification of the hydrocarbon substituted with at least one group containing at least one oxygen atom.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: September 29, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Thomas Haas, Eva Maria Wittmann
  • Patent number: 10782291
    Abstract: A microbe-specific medium, containing specific chromogenic substrates, for the detection of vancomycin-resistant enterococci in a biological sample, whereby both the detection and identification of vancomycin-resistant enterococci at the species level is achieved utilizing one sample and one test.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: September 22, 2020
    Assignee: BECTON DICKINSON AND COMPANY
    Inventors: Susan Kircher, Jon E. Salomon, Sheryl Douglas-Mckay
  • Patent number: 10780135
    Abstract: A composition of probiotics is provided which promotes weight loss and maintenance thereof. More particularly, a probiotic mixture of Lactobacillus gasseri, Lactobacillus fermentum, and Lactobacillus rhamnosus are provided to reduce body adiposity, decrease inflammation of adipose tissue, and enhance metabolism in optional combination with prebiotics and excipients such as flow agents and binders. A method of administering the probiotic composition to an individual user is also provided.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: September 22, 2020
    Inventor: Hooman M. Melamed
  • Patent number: 10780130
    Abstract: The present invention relates to an epithelial stem/progenitor cell population isolated from the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types. The invention also relates to a pharmaceutical composition comprising such an epithelial stem/progenitor cell population or a cellular extract thereof.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 22, 2020
    Assignee: CELLRESEARCH CORPORATION PTE LTD.
    Inventors: Toan Thang Phan, Ivor Jiun Lim
  • Patent number: 10774307
    Abstract: The present invention discloses a method of inducing and differentiating human skin-derived precursors into corneal endothelial-like cells. The present invention utilizes human skin-derived precursors to induce corneal endothelial-like cells that are theoretically close to normal human corneal endothelial cells successfully by co-culturing with B4G12 corneal endothelial cells. Furthermore, the obtained corneal endothelial-like cells are applied to a corneal endothelial decompensation animal model, and corneal endothelium of the animal is successfully repaired, which has an important clinical application prospect.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 15, 2020
    Inventor: Xinyi Wu
  • Patent number: 10752884
    Abstract: The disclosure relates to a method of producing induced beta cells from urine-derived cells, the method comprising providing urine-derived cells; inducing the urine-derived cells by culturing said urine-derived cells in a primary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a first period of time to obtain induced endoderm cells; inducing the induced endoderm cells by culturing said induced endoderm cells in a secondary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a second period of time to obtain induced pancreatic precursor cells; and inducing the induced pancreatic precursor cells by culturing said pancreatic precursor cells in a tertiary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a third period of time to obtain induced beta cells.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 25, 2020
    Assignee: University of South Australia
    Inventors: Yanchuang Han, Xin-Fu Zhou, WooKyung Kim, JunYong Yang, JiHee Kim
  • Patent number: 10745642
    Abstract: Provided herein are methods of recovering oil from microorganisms. The methods are useful, for example, in obtaining nutritional oils and/or lipid biofuels. The methods of recovering oil described herein include contacting a population of microorganisms with one or more enzymes under conditions that cause disruption of the microorganisms, concentrating the disrupted microorganisms, and extracting lipids from the disrupted microorganisms at high temperature in the presence of a salt and in the absence of solvent.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 18, 2020
    Assignee: MARA Renewables Corporation
    Inventors: Dorothy A. Dennis, Roberto E. Armenta
  • Patent number: 10729813
    Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 4, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Donald Freytes
  • Patent number: 10724000
    Abstract: This application relates to a method for differentiating somatic cells into multi-competent neural crest cells based on linked steps of chemically defined medium inductions. Neural crest cells are able to differentiate into numerous cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Graf, Roberto Iacone, Eva Christina Thoma
  • Patent number: 10716836
    Abstract: Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual ?-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: July 21, 2020
    Assignees: Joslin Diabetes Center Inc., Mercia Pharma, Inc.
    Inventors: Tihamer Orban, Peter Blackburn
  • Patent number: 10709787
    Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: July 14, 2020
    Assignee: NEMYSIS LIMITED
    Inventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona
  • Patent number: 10704024
    Abstract: An object of the present invention is to provide a method of simply and efficiently promoting expression of c-MPL on a surface of a mesenchymal cell. The present invention provides a method for producing a mesenchymal cell with promoted expression of a c-MPL receptor on the cell surface, comprising Step A of culturing the mesenchymal cell in a mesenchymal cell culturing basic medium comprising a c-MPL receptor active substance; and Step B of obtaining the mesenchymal cell with promoted expression of a c-MPL receptor on the cell surface.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 7, 2020
    Assignee: Adiposeeds, Inc.
    Inventors: Yumiko Matsubara, Yasuo Ikeda, Yukako Uruga
  • Patent number: 10695379
    Abstract: A method of delivering a cell derived factors to a subject is described, which includes implanting a matrix material into an intracutaneous location in the subject that results in increased vascularisation and subsequently efficient delivery of the required cell derived factors to the subject. The implanted matrix material can be loaded in-situ or alternatively pre-loaded and inserted into the appropriate location depending on requirements.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 30, 2020
    Assignee: BETA CELL TECHNOLOGIES, PTY LTD
    Inventors: John Greenwood, Patrick Toby Hewlett Coates
  • Patent number: 10690652
    Abstract: A method for detecting sickle-cell disease in an individual. A blood sample from an individual is brought into contact with an agent for inducing the sickling of red blood cells suitable for placing the red blood cells in a hypoxic condition. The blood sample is filtered through a porous membrane of which the pore size is determined to retain the sickled red blood cells, and allow the non-sickled red blood cells to pass through. The possible presence of a residue on the membrane is detected, during and/or after the filtering step. The presence indicating that the individual is suffering from sickle-cell disease.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: June 23, 2020
    Assignee: SCREENCELL
    Inventors: David Znaty, François Forestier, Georges Uzan, Cécile Aucant
  • Patent number: 10683484
    Abstract: This application describes liver stem cells (LSC), and differentiated hepatocytes, cholangiocytes, and 3D cellular structures derived therefrom. Methods for producing LSC and mature, differentiated hepatocytes and cholangiocytes in culture are provided. Also provided are cell culture systems and cell culture media for producing a homogenous population of liver stem cells that remain in an undifferentiated state over multiple passages in culture. The LSC and methods are useful for producing homogenous populations of hepatocytes and cholangiocytes for downstream applications. The LSC can be transplanted into subjects to treat liver diseases.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: June 16, 2020
    Assignees: NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Yuanyu Hu, Huck Hui Ng, Yock Young Dan
  • Patent number: 10670585
    Abstract: The present invention provides an in vitro blood vessel model for investigation of drug induced vascular injury and other vascular pathologies. The in vitro blood vessel model provides two channels separated by a porous membrane that is coated on one side by an endothelial cell layer and is coated on the other side by a smooth muscle cell layer, wherein said model is susceptible to the extravasation of red blood cells across said porous membrane due to drug induced vascular injury.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: June 2, 2020
    Inventors: David M. Hoganson, Joseph P. Vacanti, Jeffrey T. Borenstein
  • Patent number: 10660918
    Abstract: A method for enhancing an insulin like growth factor 1 receptor expression of a mesenchymal stem cell is provided. The method includes culturing a plurality of mesenchymal stem cells expressing insulin-like growth factor 1 receptors in media containing human cord blood serum to enhance the insulin like growth factor 1 receptor expression of the mesenchymal stem cells.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: May 26, 2020
    Assignee: China Medical University
    Inventors: Woei-Cherng Shyu, Chen-Huan Lin, Wei Lee, Chia-Hung Hsieh, Chung-Y. Hsu, Chang-Hai Tsai
  • Patent number: 10660329
    Abstract: The present invention relates to a method for preserving, preferably human, cells, tissues or organs in severe hypothermia, comprising a step during which the cells, tissues or organs are kept in moderate hypothermia and preferably in a hypoxic and/or hypercapnic atmosphere, before placing them in severe hypothermia.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 26, 2020
    Assignees: ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITÉ DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Zoran Ivanovic, Sandie Gerby, Marija Vlaski-Lafarge